Moshe Zilversmit, Co-Founder and CEO of Signum Surgical, commented: “We are proud to develop BioHealx, now an FDA De Novo cleared medical device for the treatment of anal fistula.

Signum Surgical Publishes Positive First-in-Human Results for BioHealx® Anal Fistula Device May 12, 2025 9:00 AM ET Pivotal data supports U.S. FDA De Novo clearance and sets the stage for U.S. launch ...

Signum Surgical Appoints Carol Burns as CEO Provided by Business Wire Mar 12, 2025 10:00am - Medtech expert to drive commercialization of BioHealx ® for the treatment of anal fistula.

Minimally invasive BioHealx technology designed to reduce surgical trauma, healing time, and total cost of care Signum Surgical, a company dedicated to developing minimally invasive ...

Signum Surgical was founded in 2016 and managed to raise €2.6m in a Series A funding round the same year. This was followed by €3.6m from grant awards in 2019 and a €2.9m funding round in 2022 .

With strong investor interest in Signum Surgical, FDA De Novo clearance is another transformative step for Moshe, Eoin and the team, and marks further progress towards bringing BioHealx to market ...

GALWAY, Ireland, May 12, 2025--Signum Surgical, a medical technology company dedicated to advancing the treatment of colorectal diseases, today announced the publication of first-in-human clinical ...

GALWAY, Ireland, March 12, 2025--Signum Surgical, (‘Signum’ or ‘the Company’) the medical technology company developing innovative solutions to treat colorectal diseases, is pleased to announce the ...

GALWAY, Ireland, July 08, 2024--Signum Surgical (‘Signum’ or ‘the Company’), a medical technology company developing innovative solutions to treat colorectal diseases, is pleased to ...